Filing Details

Accession Number:
0001209191-19-024175
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-04-09 18:59:06
Reporting Period:
2019-04-05
Accepted Time:
2019-04-09 18:59:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1662524 Akcea Therapeutics Inc. AKCA Pharmaceutical Preparations (2834) 472608175
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1692444 Paula Soteropoulos C/O Akcea Therapeutics, Inc.
22 Boston Wharf Road, 9Th Floor
Boston MA 02210
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-04-05 30,000 $6.48 30,000 No 4 M Direct
Common Stock Disposition 2019-04-05 30,000 $32.11 0 No 4 S Direct
Common Stock Acquisiton 2019-04-08 1,787 $6.48 1,787 No 4 M Direct
Common Stock Disposition 2019-04-08 1,787 $32.17 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2019-04-05 30,000 $0.00 30,000 $6.48
Common Stock Stock Option (right to buy) Disposition 2019-04-08 1,787 $0.00 1,787 $6.48
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,712,866 2025-12-15 No 4 M Direct
1,711,079 2025-12-15 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The weighted average sale price for the transaction reported was $32.1658, and the range of prices were between $32.11 and $32.20. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
  3. The shares vest as follows: 1/4th of the shares vest one year after January 1, 2015;1/48th of the shares vest monthly thereafter over the next three years.